Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model

English version České info

HIV-infected individuals must receive lifelong antiviral therapy because treatment discontinuation generally results in rapid viral rebound. The field has identified a state of latency at the level of transcription of the integrated provirus as the major mechanism of persistence. A number of drugs are now tested that aim at inducing viral transcription as a step to purge the reservoir. The assessment of viral production in cells from HIV-infected individuals with optimal viral suppression revealed the failure of SAHA/vorinostat to efficiently generate viral particle production. To further investigate and characterize the process of latency at the transcriptome level, and the response to SAHA as well as various reactivating agents, we use a model of primary CD4+ lymphocytes. The main observation from this study is that viral transcripts persist during latency, and that the accumulation of viral transcripts does not result in efficient viral protein expression upon reactivation with agents such as SAHA. Our data suggest that post-transcriptional blocks also contribute to latency, and that additional strategies need to be explored to efficiently purge the viral reservoir.

Vyšlo v časopise: Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004156
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004156

Souhrn

Zdroje

1. Cure IASSWGoH (2012) DeeksSG, AutranB, BerkhoutB, BenkiraneM, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607–614.

2. DeeksSG (2012) HIV: Shock and kill. Nature 487: 439–440.

3. SilicianoRF, GreeneWC (2011) HIV Latency. Cold Spring Harb Perspect Med 1: a007096.

4. PaceMJ, AgostoL, GrafEH, O'DohertyU (2011) HIV reservoirs and latency models. Virology 411: 344–354.

5. ShirakawaK, ChavezL, HakreS, CalvaneseV, VerdinE (2013) Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21: 277–285.

6. RasmussenTA, TolstrupM, WinckelmannA, OstergaardL, SogaardOS (2013) Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 9: 790–799.

7. MbonyeU, KarnJ (2014) Transcriptional control of HIV latency: Cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454-455C: 328–339.

8. XingS, SilicianoRF (2013) Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 18: 541–551.

9. HakreS, ChavezL, ShirakawaK, VerdinE (2012) HIV latency: experimental systems and molecular models. FEMS Microbiol Rev 36: 706–716.

10. YangHC, XingS, ShanL, O'ConnellK, DinosoJ, et al. (2009) Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 119: 3473–3486.

11. SmithMZ, WightmanF, LewinSR (2012) HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 9: 5–15.

12. PlanellesV, WolschendorfF, KutschO (2011) Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs. Curr HIV Res 9: 568–578.

13. SpinaCA, AndersonJ, ArchinNM, BosqueA, ChanJ, et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9: e1003834.

14. ArchinNM, LibertyAL, KashubaAD, ChoudharySK, KurucJD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482–485.

15. BadleyAD, SainskiA, WightmanF, LewinSR (2013) Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis 4: e718.

16. RasmussenTA, Schmeltz SogaardO, BrinkmannC, WightmanF, LewinSR, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993–1001.

17. MohammadiP, DesfargesS, BarthaI, JoosB, ZanggerN, et al. (2013) 24 hours in the life of HIV-1 in a T cell line. PLoS Pathog 9: e1003161.

18. BlazkovaJ, ChunTW, BelayBW, MurrayD, JustementJS, et al. (2012) Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 206: 765–769.

19. SahuGK, LeeK, JiJ, BracialeV, BaronS, et al. (2006) A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 355: 127–137.

20. TyagiM, PearsonRJ, KarnJ (2010) Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 84: 6425–6437.

21. ChomontN, El-FarM, AncutaP, TrautmannL, ProcopioFA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893–900.

22. LefebvreG, DesfargesS, UyttebroeckF, MunozM, BeerenwinkelN, et al. (2011) Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cell. J Virol 85: 6205–6211.

23. OcwiejaKE, Sherrill-MixS, MukherjeeR, Custers-AllenR, DavidP, et al. (2012) Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. Nucleic Acids Res 40: 10345–10355.

24. KauderSE, BosqueA, LindqvistA, PlanellesV, VerdinE (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5: e1000495.

25. FernandezG, ZeichnerSL (2010) Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 7: 266.

26. McNamaraLA, GaneshJA, CollinsKL (2012) Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J Virol 86: 9337–9350.

27. BosqueA, FamigliettiM, WeyrichAS, GoulstonC, PlanellesV (2011) Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 7: e1002288.

28. JagerS, CimermancicP, GulbahceN, JohnsonJR, McGovernKE, et al. (2012) Global landscape of HIV-human protein complexes. Nature 481: 365–370.

29. AndersS, HuberW (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.

30. WeiDG, ChiangV, FyneE, BalakrishnanM, BarnesT, et al. (2014) Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. PLoS Pathog 10: e1004071.

31. CilloAR, SobolewskiMD, BoschRJ, FyneE, PiatakMJr., et al. (2014) Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. E-pub ahead of print. doi: 10.1073/pnas.1402873111

32. BullenCK, LairdGM, DurandCM, SilicianoJD, SilicianoRF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20: 425–429.

33. ShanL, DengK, ShroffNS, DurandCM, RabiSA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491–501.

34. MariniA, HarperJM, RomerioF (2008) An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 181: 7713–7720.

35. BosqueA, PlanellesV (2009) Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113: 58–65.

36. PasternakAO, JurriaansS, BakkerM, PrinsJM, BerkhoutB, et al. (2009) Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS ONE 4: e8490.

37. YuklSA, ShergillAK, HoT, KillianM, GirlingV, et al. (2013) The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis 208: 1212–1220.

38. LafeuilladeA, KhiriH, ChadapaudS, HittingerG, HalfonP (2001) Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART. AIDS 15: 1965–1969.

39. DentonPW, LongJM, WietgrefeSW, SykesC, SpagnuoloRA, et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10: e1003872.

40. NorthTW, HigginsJ, DeereJD, HayesTL, VillalobosA, et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84: 2913–2922.

41. Van LintC, BouchatS, MarcelloA (2013) HIV-1 transcription and latency: an update. Retrovirology 10: 67.

42. MarsdenMD, BurkeBP, ZackJA (2011) HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology 417: 394–399.

43. PaceMJ, GrafEH, AgostoLM, MexasAM, MaleF, et al. (2012) Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency. PLoS Pathog 8: e1002818.

44. ContrerasX, SchwenekerM, ChenCS, McCuneJM, DeeksSG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782–6789.

45. ReuseS, CalaoM, KabeyaK, GuiguenA, GatotJS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4: e6093.

46. XingS, BullenCK, ShroffNS, ShanL, YangHC, et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85: 6060–6064.

47. Beliakova-BethellN, ZhangJX, SinghaniaA, LeeV, TerryVH, et al. (2013) Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 27: 29–37.

48. VandergeetenC, FromentinR, DaFonsecaS, LawaniMB, SeretiI, et al. (2013) Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121: 4321–4329.

49. ChunTW, JustementJS, LempickiRA, YangJ, DennisGJr, et al. (2003) Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 100: 1908–1913.

50. LassenKG, RamyarKX, BaileyJR, ZhouY, SilicianoRF (2006) Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2: e68.

51. LiM, KaoE, GaoX, SandigH, LimmerK, et al. (2012) Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 491: 125–128.

52. HuangJ, WangF, ArgyrisE, ChenK, LiangZ, et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13: 1241–1247.

53. Iglesias-UsselM, VandergeetenC, MarchionniL, ChomontN, RomerioF (2013) High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4+ T Cells in Virally Suppressed Subjects. J Virol 87: 9148–9158.

54. Sherrill-MixS, LewinskiMK, FamigliettiM, BosqueA, MalaniN, et al. (2013) HIV latency and integration site placement in five cell-based models. Retrovirology 10: 90.

55. LovenJ, OrlandoDA, SigovaAA, LinCY, RahlPB, et al. (2012) Revisiting global gene expression analysis. Cell 151: 476–482.

56. MartinM (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 17: 10–12.

57. SchmiederR, EdwardsR (2011) Quality control and preprocessing of metagenomic datasets. Bioinformatics 27: 863–864.

58. KimD, PerteaG, TrapnellC, PimentelH, KelleyR, et al. (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14: R36.

59. BenjaminiY, HochbergY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57: 289–300.

60. BrassAL, DykxhoornDM, BenitaY, YanN, EngelmanA, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926.

61. KonigR, ZhouY, EllederD, DiamondTL, BonamyGM, et al. (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49–60.

62. ZhouH, XuM, HuangQ, GatesAT, ZhangXD, et al. (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4: 495–504.

63. YeungML, HouzetL, YedavalliVS, JeangKT (2009) A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem 284: 19463–19473.

64. DobinA, DavisCA, SchlesingerF, DrenkowJ, ZaleskiC, et al. (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15–21.